首页> 外文期刊>Heart Views: The Official Journal of the Gulf Heart Association >Clinical Outcome, and Survival Between Primary Percutaneous Coronary Intervention Versus Fibrinolysis in Patients Older Than 60 Years with Acute Myocardial Infarction
【24h】

Clinical Outcome, and Survival Between Primary Percutaneous Coronary Intervention Versus Fibrinolysis in Patients Older Than 60 Years with Acute Myocardial Infarction

机译:60岁以上急性心肌梗死患者的原发性经皮冠状动脉介入治疗与纤溶之间的临床疗效及生存率

获取原文
           

摘要

Objective:The aim of the present study was to compare the short-term and 6-month clinical outcome, and survival in patients older than 60 years with ST-elevation myocardial infarction randomized to either primary percutaneous coronary intervention (PPCI) or thrombolysis.Materials and Methods:82 patients with STEMI older than 60 years were randomized to either primary PCI or thrombolysis from September 2006 to August 2008. Angiograms were reviewed by two interventionalists not involved in the study. Patients randomized to primary PCI received Aspirin and 600 mg Clopidogrel. Heparin was administered in conjunction with PCI. Patients randomized to thrombolysis received Aspirin followed by streptokinase infusion for one hour. Rescue PCI was considered if there was ongoing pain and ST-segment resolution was <50% at 90 min. after initiation of thrombolysis or chest pain recurred with ST-segment elevation within 24 hours. All patients were followed up for 6 months. End points were reinfarction and cardiac death using competing-risks regression estimation.Results:The mean time from hospital admission to start of streptokinase infusion was 31 ± 15 min and door to balloon time was 70 ± 25 min. There was no significant difference between the groups in the number of deaths and reinfarctions at 6 months. As expected, the fibrinolysis group had a higher rate of revascularization and heart failure.Conclusion:The higher rates of heart failure and need for revascularization in the fibrinolysis group reinforces benefits of PPCI in patients older than 60 years. PPCI in those who are 60 years and above with AMI is safe and cost effective.
机译:目的:本研究的目的是比较60岁以上ST抬高型心肌梗死随机分为原发性经皮冠状动脉介入治疗(PPCI)或溶栓治疗的患者的短期和6个月临床结果以及生存率。方法和方法:从2006年9月至2008年8月,将82例60岁以上STEMI患者随机分为原发性PCI或溶栓治疗。两名未介入研究的介入专家对血管造影进行了回顾。随机分配至原发性PCI的患者接受阿司匹林和600 mg氯吡格雷治疗。肝素与PCI联合给药。随机接受溶栓治疗的患者接受阿司匹林,然后输注链激酶一小时。如果持续疼痛且在90分钟时ST段分辨率低于50%,则考虑进行急救PCI。溶栓开始后或24小时内ST段抬高复发胸痛。所有患者均获随访6个月。结果:使用竞争风险回归估算得出再梗塞和心源性死亡。结果:从入院到开始注射链激酶的平均时间为31±15分钟,从门到球囊的平均时间为70±25分钟。两组之间在6个月时的死亡和再梗死数目没有显着差异。正如预期的那样,纤维蛋白溶解组的血运重建和心力衰竭发生率更高。结论:纤维蛋白溶解组的心力衰竭发生率较高,需要血管重建,这增强了60岁以上患者的PPCI获益。患有AMI的60岁及以上人群中的PPCI安全且具有成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号